Company intelligence / Profile preview

CMD-COAT SA

Ownership: Private
Development stage: Preclinical

Overview

No detailed clinical results publicly disclosed yet. The company emphasizes innovative patented technology with promising properties to extend catheter durability by preventing two major complications—thrombosis and infections[1][2][3].

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Bioactive surface coatings with antimicrobial, anti-thrombotic, antifouling propertiesHydrosoluble and biocompatible polymer-based coatings
Industry: Chemicals & Materials

Drug pipeline

1 asset

COATI-X

Pre-clinical

Indications: Catheter-related infections, Catheter-related thrombosis

Partnerships

Collaboration with FRESCI by SCIENCE&STRATEGY SL under European Innovation Council funding[3]Close ties with University Hospital Liège cardiology department[2]

Beyond the preview

Go deeper on CMD-COAT SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMD-COAT SA.

Explore the full profile